Jason B. Litten

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

J.C. Soria, Rastilav Bahleda, Bárbara Adamo et al. · Annals of Oncology · 2014 · 169 citations · Full text

Oncology, Phase I/iia Study, Pharmacology +6

Acute lymphoblastic leukemia presenting in fulminant hepatic failure

Jason B. Litten, Maria M. Rodríguez, Vincenzo Maniaci · Pediatric Blood & Cancer · 2005 · 30 citations

Activated NOTCH2 is Overexpressed in Hepatoblastomas: An Immunohistochemical Study

Jason B. Litten, Tina T.-L. Chen, Roger A. Schultz et al. · Pediatric and Developmental Pathology · 2011 · 29 citations

Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, Jean‐Frédéric Blanc, Steven A. Miles et al. · The Oncologist · 2017 · 22 citations · Full text

A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer

Ignace Vergote, Russell J. Schilder, Charles H. Pippitt et al. · Gynecologic Oncology · 2014 · 21 citations · Full text

Phase 1B, Pegylated Liposomal Doxorubicin, Medicine +8